More evidence for dolutegravir as first-line ART for all

Estill, Janne Anton Markus; Bertisch, Barbara

doi:10.1016/S2352-3018(19)30414-X

Scientific article

Comment

English

More evidence for dolutegravir as first-line ART for all

ContributorsEstill, Janne Anton Markus; Bertisch, Barbara

Published inThe Lancet HIV, vol. 7, no. 3, p. e154-e155

Publication date2020

Keywords

Africa South of the Sahara
Alkynes
Benzoxazines
Cyclopropanes
HIV Infections
Heterocyclic Compounds, 3-Ring
Humans
Oxazines
Piperazines
Pyridones
Risk Assessment

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de santé et médecine communautaires / Institut de santé globale

Research groups

Maladies infectieuses et modèles mathématiques (988)

Funding

Swiss National Science Foundation - 163878

Citation (ISO format)

ESTILL, Janne Anton Markus, BERTISCH, Barbara. More evidence for dolutegravir as first-line ART for all. In: The Lancet HIV, 2020, vol. 7, n° 3, p. e154–e155. doi: 10.1016/S2352-3018(19)30414-X

Article (Accepted version)

Article (Published version)

Identifiers

PID : unige:153650
DOI : 10.1016/S2352-3018(19)30414-X
PMID : 32035042

Journal ISSN2352-3018

146views

23downloads

Creation04/29/2021 5:35:00 PM

First validation04/29/2021 5:35:00 PM

Update time03/16/2023 12:58:38 AM

Status update03/16/2023 12:58:37 AM

Last indexation10/31/2024 10:40:01 PM

Archive ouverte UNIGE

More evidence for dolutegravir as first-line ART for all

Technical informations